ATE361094T1 - Chemische igf-i-zusammensetzung zur behandlung und prävention von neurodegenerativen erkrankungen - Google Patents

Chemische igf-i-zusammensetzung zur behandlung und prävention von neurodegenerativen erkrankungen

Info

Publication number
ATE361094T1
ATE361094T1 AT03744388T AT03744388T ATE361094T1 AT E361094 T1 ATE361094 T1 AT E361094T1 AT 03744388 T AT03744388 T AT 03744388T AT 03744388 T AT03744388 T AT 03744388T AT E361094 T1 ATE361094 T1 AT E361094T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
neurodegenerative diseases
igf
chemical composition
Prior art date
Application number
AT03744388T
Other languages
English (en)
Inventor
Lopez C Lopez
Diaz E M Carro
Alem N I Torres
Duran J J Torrado
Duran S Torrado
Celia Carrascosa
Original Assignee
Consejo Superior Investigacion
Univ Madrid Complutense
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion, Univ Madrid Complutense filed Critical Consejo Superior Investigacion
Application granted granted Critical
Publication of ATE361094T1 publication Critical patent/ATE361094T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT03744388T 2002-02-28 2003-02-21 Chemische igf-i-zusammensetzung zur behandlung und prävention von neurodegenerativen erkrankungen ATE361094T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200200491A ES2207387B1 (es) 2002-02-28 2002-02-28 Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.

Publications (1)

Publication Number Publication Date
ATE361094T1 true ATE361094T1 (de) 2007-05-15

Family

ID=27838351

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03744388T ATE361094T1 (de) 2002-02-28 2003-02-21 Chemische igf-i-zusammensetzung zur behandlung und prävention von neurodegenerativen erkrankungen

Country Status (13)

Country Link
US (1) US20050208126A1 (de)
EP (1) EP1488801B1 (de)
JP (1) JP2005529083A (de)
AT (1) ATE361094T1 (de)
AU (1) AU2003209777B2 (de)
CA (1) CA2477593C (de)
DE (1) DE60313593T2 (de)
DK (1) DK1488801T3 (de)
ES (2) ES2207387B1 (de)
MX (1) MXPA04008402A (de)
PL (1) PL373382A1 (de)
PT (1) PT1488801E (de)
WO (1) WO2003077940A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833513B2 (en) * 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
JP5921052B2 (ja) * 2004-12-03 2016-05-24 ロード アイランド ホスピタル アルツハイマー病の検査
JPWO2008111520A1 (ja) * 2007-03-09 2010-06-24 国立大学法人 長崎大学 寿命延長関連遺伝子およびその用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
HU217543B (hu) * 1992-06-12 2000-02-28 Albert Einstein College Of Medicine Of Yeshiva University Eljárás perifériás neuropátia kezelésére és megelőzésére alkalmas gyógyászati készítmények előállítására, valamint inzulinszerű növekedési faktor I-et és kemoterápiás szert tartalmazó gyógyászati készítmények
US5705197A (en) * 1994-05-16 1998-01-06 The United States Of America As Represented By The Secretary Of The Army Extraction process for producing PLGA microspheres
US5888551A (en) * 1995-12-11 1999-03-30 University Of Miami Hair growth stimulating composition
JP4642946B2 (ja) * 1996-12-20 2011-03-02 アルザ コーポレイション ゲル組成物および方法
JPH10273447A (ja) * 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
US5861149A (en) * 1997-06-04 1999-01-19 Polyheal Ltd. Methods for wound treatment
AU1384199A (en) * 1997-11-07 1999-05-31 Chiron Corporation Method for producing igf-1 sustained-release formulations
ES2146530B1 (es) * 1997-12-26 2001-04-16 Consejo Superior Investigacion Utilizacion del factor de crecimiento igf-i en la fabricacion de composiciones utiles en el tratamiento de la ataxia cerebelar.
JP2002535967A (ja) * 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体

Also Published As

Publication number Publication date
JP2005529083A (ja) 2005-09-29
CA2477593C (en) 2012-05-15
DE60313593D1 (de) 2007-06-14
EP1488801A1 (de) 2004-12-22
DE60313593T2 (de) 2008-01-31
CA2477593A1 (en) 2003-09-25
US20050208126A1 (en) 2005-09-22
WO2003077940A1 (es) 2003-09-25
PL373382A1 (en) 2005-08-22
ES2287500T3 (es) 2007-12-16
AU2003209777A1 (en) 2003-09-29
PT1488801E (pt) 2007-08-14
ES2207387A1 (es) 2004-05-16
ES2207387B1 (es) 2005-07-16
EP1488801B1 (de) 2007-05-02
DK1488801T3 (da) 2007-09-10
MXPA04008402A (es) 2005-07-27
AU2003209777B2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
ATE406893T1 (de) Pharmazeutische zusammensetzung (kit) enthaltend dihydropyridinonverbindungen und eine verbindung mit immunmodulatorischer (oder antiinflammatorischer) wirkung und ihre verwendung
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
TW200502221A (en) Novel lactams and uses thereof
TNSN04165A1 (en) Substituted hydroxyethylamines
SE0104340D0 (sv) New compounds
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
DE60233433D1 (de) PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN
SE0104331D0 (sv) Novel compounds
DE60221283D1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
CY1110401T1 (el) Παραγωγα των 1-φαινυλαλκανοκαρβοξυλικων οξεων για την αντιμετωπιση των νευροεκφυλιστικων νοσων
DE60323510D1 (de) Implantat für den transport und die freigabe von pharmakologisch aktiven substanzen
DE60313593D1 (de) Chemische igf-i-zusammensetzung zur behandlung und prävention von neurodegenerativen erkrankungen
EP1201240A3 (de) Heterozyklische Verbindungen verwendbar als pharmazeutische Mittel
TW200602297A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
TW200504036A (en) Novel lactams and uses thereof
DE60231054D1 (de) Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält
DE602005008417D1 (de) Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
PL1652836T3 (pl) Diamidy nie-α-aminokwasów użyteczne jako środki wspomagające do podawania środków biologicznie czynnych
TW200509915A (en) Novel oxazoles, their manufacture and use as pharmaceutical agents
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
SE0302666D0 (sv) Novel Compounds
BR0214626A (pt) Métodos de produção e utilização de theflavina, 3-galato de theflavina, 3'-galato de theaflavina e 3,3'-digalato de theaflavina e suas misturas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1488801

Country of ref document: EP